745 results on '"Telegdy G"'
Search Results
202. The effects of atrial natriuretic peptide on food-reinforced conditioning in rats. Interactions with neurotransmitters
- Author
-
Bidzseranova, A., Gueron, J., Toth, G., and Telegdy, G.
- Published
- 1993
- Full Text
- View/download PDF
203. Effects of Calcitonin Gene-Related Peptide on Acute and Chronic Effects of Morphine
- Author
-
Azarov, A. V., Szabo, G., Czako, L., and Telegdy, G.
- Published
- 1995
- Full Text
- View/download PDF
204. Effects of secretin on acute and chronic effects of morphine
- Author
-
Babarczy, E., Szabo, G., and Telegdy, G.
- Published
- 1995
- Full Text
- View/download PDF
205. Cocaine-induced elevation of plasma corticosterone is mediated by different neurotransmitter systems in rats
- Author
-
Sarnyai, Z., Biro, E., and Telegdy, G.
- Published
- 1993
- Full Text
- View/download PDF
206. The effects of brain natriuretic peptide-32 on electro-convulsive shock-induced amnesia in rats. The role of neurotransmitters
- Author
-
Bidzseranova, A., Varga, J., and Telegdy, G.
- Published
- 1993
- Full Text
- View/download PDF
207. Behavioral, neuroendocrine and thermoregulatory actions of apelin-13
- Author
-
Jászberényi, M., Bujdosó, E., and Telegdy, G.
- Subjects
- *
NEUROTRANSMITTERS , *CATECHOLAMINES , *NITRIC oxide , *DOPAMINE , *NAPS (Sleep) - Abstract
Abstract: As the distribution of apelinergic neurons in the brain suggests an important role of apelin-13 in the regulation of neuroendocrine processes, in the present experiments the effects of this recently identified neuropeptide on the open-field activity, the hypothalamo–pituitary–adrenal (HPA) system and the body temperature were investigated. I.c.v. administration of apelin-13 (1–10μg) to rats caused significant increases in square crossing, rearing, plasma corticosterone release and core temperature, whereas it did not influence the spontaneous motor activity during telemetric observation. To determine the mediation of the actions of apelin, a corticotropin-releasing hormone (CRH) antagonist, the nonselective dopamine antagonist haloperidol, the selective dopamine D1 receptor antagonist SCH-23390 and the nitric oxide synthase inhibitor Nω-nitro-l-arginine-methyl ester (l-NAME) were administered to the rats. The apelin-evoked HPA activation was diminished by preadministration of the CRH antagonist, while the dopamine antagonist and l-NAME attenuated only the square crossing and rearing induced by apelin-13. To characterize the transmission of the thermoregulatory action of apelin, animals were pretreated either with l-NAME, the CRH antagonist or with the cyclooxygenase inhibitor noraminophenazone. l-NAME and the CRH antagonist did not cause significant inhibition of the apelin-evoked increase in core temperature, while the cyclooxygenase inhibitor, applied 30 min before peptide treatment, did not prove effective in preventing the apelin-evoked thermoregulatory response, whereas when it was administered 2 h after the peptide treatment, it transiently and significantly reduced the hyperthermic response. The present data suggest that apelin-13 plays an important role in the regulation of behavioral, endocrine and homeostatic responses in the CNS, and dopamine, nitric oxide and prostaglandins seem to take part in the mediation of its effects. Since the corticosterone response could be blocked by the CRH antagonist, it is likely to be mediated through the activation of the CRH neurons. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
208. The effects of β-(TYR 9)melanotropin-(9–18) and H-PHE-ILE-TYR-HIS-SER-TYR-LYS-OH on the analgesic action of morphine
- Author
-
Telegdy, G., Vécsei, L., Schally, A.V., and Coy, D.H.
- Published
- 1983
- Full Text
- View/download PDF
209. Inhibition of haloperidol-induced catalepsy by cholecystokinin octapeptides after central administration to rats
- Author
-
Kádár, T., Penke, B., Kovács, K., and Telegdy, G.
- Published
- 1985
- Full Text
- View/download PDF
210. Effect of a selective - opioid agonist, d-pen 2-d-pen 5 - enkephalin (DPDPE), on grooming and sniffing activity
- Author
-
Kriván, M., Nyolczas, N., Sarnyai, Z., Szabó, G., Gulya, K., Kovács, G.L., and Telegdy, G.
- Published
- 1989
- Full Text
- View/download PDF
211. Highly selective mu-opioid antagonist somatostain analogue (CTOP) inhibits electrical self-stimulation in rats
- Author
-
Sarnyai, Z., Kriván, M., Schwarzberg, H., Szabó, G., and Telegdy, G.
- Published
- 1991
- Full Text
- View/download PDF
212. Effects of atrial natriuretic peptide on fear motivated learning in rats
- Author
-
Bidseranova, A. and Telegdy, G.
- Published
- 1991
- Full Text
- View/download PDF
213. Electroconvulsive shock-induced amnesia. Action of neuropeptides
- Author
-
Telegdy, G.
- Published
- 1994
- Full Text
- View/download PDF
214. The role of endogenous calcitonin generelated peptide (CGRP) on the behaviour of rats
- Author
-
Kovács, A. and Telegdy, G.
- Published
- 1993
- Full Text
- View/download PDF
215. Effects of galanin on picrotoxin-kindled seizure syndrome
- Author
-
Mazarati, A.M., Halászi, E., and Telegdy, G.
- Published
- 1992
- Full Text
- View/download PDF
216. Transmitter-mediated action of CGRP on open field activity in rats
- Author
-
Kovács, A. and Telegdy, G.
- Published
- 1992
- Full Text
- View/download PDF
217. Transmitter mediated action of galanin on consolidation of the passive avoidance response in rats
- Author
-
Gábos, L. and Telegdy, G.
- Published
- 1992
- Full Text
- View/download PDF
218. The role of endogenous CRH in the mediation of the neuroendocrine and behavioral response to CCK in rats
- Author
-
Biró, É., Sarnyai, Z., Penke, B., and Telegdy, G.
- Published
- 1992
- Full Text
- View/download PDF
219. CGRP delays the extinction of an active avoidance response in rats
- Author
-
Kovács, A. and Telegdy, G.
- Published
- 1994
- Full Text
- View/download PDF
220. Memory Enhancement with Kynurenic Acid and Its Mechanisms in Neurotransmission.
- Author
-
Martos D, Tuka B, Tanaka M, Vécsei L, and Telegdy G
- Abstract
Kynurenic acid (KYNA) is an endogenous tryptophan (Trp) metabolite known to possess neuroprotective property. KYNA plays critical roles in nociception, neurodegeneration, and neuroinflammation. A lower level of KYNA is observed in patients with neurodegenerative diseases such as Alzheimer's and Parkinson's diseases or psychiatric disorders such as depression and autism spectrum disorders, whereas a higher level of KYNA is associated with the pathogenesis of schizophrenia. Little is known about the optimal concentration for neuroprotection and the threshold for neurotoxicity. In this study the effects of KYNA on memory functions were investigated by passive avoidance test in mice. Six different doses of KYNA were administered intracerebroventricularly to previously trained CFLP mice and they were observed for 24 h. High doses of KYNA (i.e., 20-40 μg/2 μL) significantly decreased the avoidance latency, whereas a low dose of KYNA (0.5 μg/2 μL) significantly elevated it compared with controls, suggesting that the low dose of KYNA enhanced memory function. Furthermore, six different receptor blockers were applied to reveal the mechanisms underlying the memory enhancement induced by KYNA. The series of tests revealed the possible involvement of the serotonergic, dopaminergic, α and β adrenergic, and opiate systems in the nootropic effect. This study confirmed that a low dose of KYNA improved a memory component of cognitive domain, which was mediated by, at least in part, four systems of neurotransmission in an animal model of learning and memory.
- Published
- 2022
- Full Text
- View/download PDF
221. Antidepressant-like effects of kynurenic acid in a modified forced swim test.
- Author
-
Tanaka M, Bohár Z, Martos D, Telegdy G, and Vécsei L
- Subjects
- Animals, Antidepressive Agents therapeutic use, Depression metabolism, Disease Models, Animal, Kynurenic Acid therapeutic use, Male, Mice, Inbred Strains, Receptors, Dopamine metabolism, Receptors, GABA-A metabolism, Receptors, Serotonin, 5-HT2 metabolism, Antidepressive Agents pharmacology, Behavior, Animal drug effects, Depression drug therapy, Kynurenic Acid pharmacology, Motor Activity drug effects, Swimming
- Abstract
Background: Kynurenic acid (KYNA) is an L-tryptophan metabolite with neuromodulatory activities, regulating the release of neurotransmitters such as glutamate, dopamine (DA), and acetylcholine (Ach). Dysregulation of the kynurenine pathway has been associated with neurodegenerative, neurological, and psychological disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, major depressive disorder, and schizophrenia., Methods: The antidepressant-like effects of KYNA were studied with a modified mouse forced swimming test (FST), and the potential involvement of the serotonin (SER), norepinephrine, DA, Ach, N-methyl-D-aspartate, or gamma-aminobutyric acid subunit A (GABA
A ) receptors in its antidepressant-like effect was assayed by modified combination mouse FST. In combination studies, the mice were pretreated with the respective receptor antagonist, cyproheptadine (CPH), phenoxybenzamine, yohimbine, propranolol, haloperidol (HPD), atropine, MK-801, or bicuculline (BCL)., Results: The FST revealed that KYNA reversed immobility, climbing, and swimming times, suggesting the antidepressant-like effects of KYNA. Furthermore, the combination studies showed that CPH prevented the antidepressant-like effects of KYNA on immobility, climbing, and swimming times, whereas HPD reduced climbing time and BCL influenced immobility and climbing times and prevented the effects of KYNA on swimming time., Conclusions: The results demonstrated, for the first time, the presence of antidepressant-like effects of KYNA in a modified mouse FST. Furthermore, modified combination FST showed that the antidepressant-like actions of KYNA strongly interacted with 5-hydroxytryptamine type 2 SER-ergic receptors, weakly interacted with D2 , D3 , D4 DA-ergic receptors, and interacted moderately with GABAA receptors.- Published
- 2020
- Full Text
- View/download PDF
222. Changes in striatal dopamine release and locomotor activity following acute withdrawal from chronic nicotine are mediated by CRF1, but not CRF2, receptors.
- Author
-
Buzás A, Bokor P, Balangó B, Pintér D, Palotai M, Simon B, Csabafi K, Telegdy G, Szabó G, and Bagosi Z
- Subjects
- Animals, Corpus Striatum metabolism, Corticotropin-Releasing Hormone pharmacology, Dopamine metabolism, Locomotion physiology, Male, Motor Activity, Peptide Fragments pharmacology, Rats, Rats, Wistar, Substance Withdrawal Syndrome metabolism, Dopaminergic Neurons metabolism, Nicotine metabolism, Receptors, Corticotropin-Releasing Hormone metabolism
- Abstract
The aim of the present study was to investigate the participation of corticotropin-releasing factor (CRF) receptors (CRF1 and CRF2) in the alterations of the dorsal and ventral striatal dopamine release and the vertical and horizontal locomotor activity observed in rats following chronic nicotine treatment and consequent acute withdrawal. In this purpose, male Wistar rats were exposed to repeated intraperitoneal (ip) injection with nicotine or saline solution for 7 days. On the 8th day or the 9th day the rats were injected intracerebroventricularly (icv) with selective CRF1 antagonist antalarmin or selective CRF2 antagonist astressin
2B or saline solution. Thirty minutes after the icv injection the changes of the horizontal and vertical locomotor activity were recorded in an in vivo conducta system. Immediately after the behavioral recordings the changes of the dorsal and ventral striatal dopamine release were determined in an in vitro superfusion system. On the 8th day, the horizontal and vertical locomotor activities and the dorsal and ventral striatal dopamine releases increased significantly in nicotine-treated rats, compared to the saline-treated ones. On the 9th day, the horizontal locomotor activity and the dorsal striatal dopamine release increased significantly, whereas the vertical locomotor activity and the ventral striatal dopamine release decreased significantly in nicotine-treated rats, compared to the saline-treated ones. All the changes observed were attenuated significantly by antalarmin, but not astressin2B . The present study demonstrates that the changes of striatal dopamine release and locomotor activity observed following chronic nicotine treatment and consequent acute withdrawal are mediated by CRF1, but not CRF2, receptor., (Copyright © 2018 Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
223. The effects of the urocortins on the hypothalamic-pituitary-adrenal axis - similarities and discordancies between rats and mice.
- Author
-
Bagosi Z, Csabafi K, Karasz G, Jászberényi M, Földesi I, Siska A, Szabó G, and Telegdy G
- Subjects
- Animals, Hypothalamo-Hypophyseal System drug effects, Hypothalamus drug effects, Male, Mice, Pituitary-Adrenal System drug effects, Rats, Rats, Wistar, Urocortins pharmacology, Adrenocorticotropic Hormone metabolism, Hypothalamo-Hypophyseal System metabolism, Hypothalamus metabolism, Pituitary-Adrenal System metabolism, Urocortins metabolism
- Abstract
The urocortins (Ucn I, Ucn II and Ucn III) are structural analogues of corticotropin-releasing factor (CRF). The aim of our present experiments was to compare the effects of the urocortins on the hypothalamic-pituitary-adrenal (HPA) axis in rats and mice, including the hypothalamic adrenocorticotropic hormone (ACTH) secretagogues, such as CRF and arginine vasopressin (AVP). Therefore, male CFLP mice and male Wistar rats were injected intracerebroventricularly (icv) with 0.5, 1, 2 and 5 μg/2 μl of Ucn I, Ucn II or Ucn III. After 30 min the animals were decapitated, and then, hypothalamic CRF and AVP concentrations and plasma ACTH and corticosterone (CORT) levels were measured. All measurements were performed by enzyme-linked immunosorbent assays (ELISA), except that of the plasma CORT level, which was determined by chemofluorescent assay. Ucn I increased significantly the hypothalamic CRF and AVP concentrations in both rats and mice. Ucn II and Ucn III influenced significantly only the hypothalamic CRF concentration in rats, without affecting the hypothalamic AVP concentration. In contrast, Ucn II and Ucn III increased significantly only the hypothalamic AVP concentration in mice, without affecting the hypothalamic CRF concentration. The hypothalamic changes were reflected more or less accurately by changes of the plasma ACTH and CORT levels. The present experiments demonstrate that the urocortins regulate the HPA axis centrally via modulation of the hypothalamic ACTH secretagogues and that there are some similarities and discordancies between rats and mice regarding this regulation., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
224. Kisspeptin modulates pain sensitivity of CFLP mice.
- Author
-
Csabafi K, Bagosi Z, Dobó É, Szakács J, Telegdy G, and Szabó G
- Subjects
- Analgesics, Opioid administration & dosage, Animals, Kisspeptins antagonists & inhibitors, Mice, Morphine administration & dosage, Nociception physiology, Pain genetics, Pain physiopathology, Pain Threshold drug effects, Receptors, Kisspeptin-1 antagonists & inhibitors, Drug Tolerance genetics, Kisspeptins genetics, Nociception drug effects, Pain drug therapy
- Abstract
Kisspeptin, a hypothalamic neuropeptide, is a member of the RF-amide family, which have been known to modify pain sensitivity in rodents. The aim of the present study was to investigate the effect of kisspeptin-13 (KP-13), an endogenous derivative of kisspeptin, on nociception in adult male and female CFLP mice and the possible interaction of KP-13 with morphine on nociception. Mice were injected with different doses of KP-13, 30, 60 and 120 min after of which the nociceptive sensitivity were assessed via the tail-flick test. To investigate the receptor involved in the mediation a kisspeptin receptor antagonist (KP-234) pretreatment was applied before KP-13 administration. Furthermore, we investigated the effect of KP-13 on the acute antinociceptive effect of morphine, on acute morphine tolerance and on naloxone-precipitated withdrawal. Last, the Von Frey test was used in order to assess KP-13's effect on mechanical nociception. Our results showed that KP-13 decreased the nociceptive threshold of both males and females independent of sex, which was prevented by KP-234. Furthermore, KP-13 treatment depressed the acute antinociceptive effect of morphine and attenuated the development of morphine tolerance. KP-13 also induced a mechanical hypersensitivity. These data underlie kisspeptin's hyperalgesic action and argues for the role of kisspeptin receptor 1 in the mediation of its action. Furthermore, our results suggest that central KP-13 administration can modify the acute effects of morphine., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
225. Anxiolytic- and antidepressant-like actions of Urocortin 2 and its fragments in mice.
- Author
-
Bagosi Z, Csabafi K, Balangó B, Pintér D, Szolomájer-Csikós O, Bozsó Z, Tóth G, Telegdy G, and Szabó G
- Subjects
- Animals, Anxiety physiopathology, Depression physiopathology, Disease Models, Animal, Dose-Response Relationship, Drug, Freezing Reaction, Cataleptic drug effects, Injections, Intraventricular, Male, Maze Learning drug effects, Mice, Mice, Inbred C57BL, Peptides therapeutic use, Swimming psychology, Urocortins chemistry, Anti-Anxiety Agents therapeutic use, Antidepressive Agents therapeutic use, Anxiety drug therapy, Depression drug therapy, Urocortins therapeutic use
- Abstract
The aim of the present study was to investigate the potential anxiolytic- and antidepressant-like actions of Urocortin 2 (Ucn2) and its two fragments, Ucn2 (1-21) and Ucn2 (22-38), in mice, in an attempt to identify the biologically active sequence of this 38 amino acid neuropeptide. In this purpose, male C57BL/6 mice were treated intracerebroventricularly (icv) with 0.125, 0.25, 0.5 and 1 µg/2 µl of Ucn2, Ucn2 (1-21) or Ucn2 (22-38). After 30 min, the mice were evaluated in an elevated plus-maze test and a forced swim test for anxiety- and depression-like behavior, respectively. Each test lasted 5 min. Ucn2 at dose of 0.25 µg/2 µl and Ucn2 (1-21) at dose of 0.125 µg/2 µl, but not Ucn2 (22-38), increased significantly the number of entries into and the time spent in the open-arms, without influencing the total number of entries. In parallel, the same doses of Ucn2 and Ucn2 (1-21), but not Ucn2 (22-38), increased significantly the climbing and the swimming activity, while decreasing significantly the time of immobility. In addition, Ucn2 at doses of 0.125 µg/2 µl and 0.5 µg/2 µl decreased significantly the time of immobility, but they did not change the other parameters. The present study demonstrates that Ucn2 exerts anxiolytic- and antidepressant-like effects in C57BL/6 mice, which are mediated by the N-terminal, but not the C-terminal fragment of the peptide. The establishment of the smallest active sequence by further fragmentation of Ucn2 (1-21) may allow the synthesis of new anxiolytic and antidepressant drugs., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
226. The effects of CRF and urocortins on the sociability of mice.
- Author
-
Bagosi Z, Karasz G, Czébely-Lénárt A, Csabafi K, Jászberényi M, and Telegdy G
- Subjects
- Animals, Behavior, Animal drug effects, Corticotropin-Releasing Hormone drug effects, Male, Mice, Peptide Fragments, Peptides, Cyclic, Pyrimidines, Pyrroles, Receptors, Corticotropin-Releasing Hormone metabolism, Social Behavior, Urocortins pharmacology, Corticotropin-Releasing Hormone metabolism, Corticotropin-Releasing Hormone pharmacology, Urocortins metabolism
- Abstract
The aim of our study was to determine the role of corticotropin-releasing factor (CRF), the urocortins (Ucn1, Ucn2 and Ucn3) and their receptors (CRF
1 and CRF2 ) in the sociability of mice. Male CFLP mice were administered intracerebroventricularly (icv) with CRF and urocortins alone or in combination with antalarmin (specific CRF1 antagonist) and astressin2B (specific CRF2 antagonist) and then investigated in a Crawley social interaction test arena, that consists of three chambers. An unknown male in a cage was put in the first chamber and an empty cage was put in the opposite chamber. The tested male was habituated with the middle chamber for 5min and then allowed to explore the remaining chambers for 5min, during which the number of entries and the time of interaction were measured. Intracerebroventricular administration of CRF decreased significantly the number of entries and the time of interaction with the unknown male and these effects were blocked by antalarmin, but not astressin2B . In contrast, central administration of Ucn1 increased significantly the number of entries into the chamber of the unknown male, without changing the time of interaction and this effect was blocked by astressin2B , but not antalarmin. Central administration of Ucn2 and Ucn3 didn't influence remarkably the number of entries, but it reduced the time of interaction between the male mice. Our study suggests that CRF and Ucn1 may play important, but different roles in sociability, and that Ucn2 and Ucn3, playing similar roles, must be also involved in social interactions., (Copyright © 2017 Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
227. The effects of CRF and urocortins on the preference for social novelty of mice.
- Author
-
Bagosi Z, Czébely-Lénárt A, Karasz G, Csabafi K, Jászberényi M, and Telegdy G
- Subjects
- Animals, Animals, Outbred Strains, Corticotropin-Releasing Hormone administration & dosage, Exploratory Behavior drug effects, Female, Male, Mice, Peptide Fragments administration & dosage, Peptides, Cyclic administration & dosage, Pyrimidines administration & dosage, Pyrroles administration & dosage, Receptors, Corticotropin-Releasing Hormone antagonists & inhibitors, Receptors, Corticotropin-Releasing Hormone physiology, Urocortins administration & dosage, Corticotropin-Releasing Hormone physiology, Exploratory Behavior physiology, Interpersonal Relations, Urocortins physiology
- Abstract
The aim of the present study was to determine the role of corticotropin-releasing factor (CRF), the urocortins (UCN 1, UCN 2 and UCN 3) and their receptors (CRF
1 and CRF2 ) in the preference for social novelty of mice. Male CFLP mice were administered intracerebroventricularly (ICV) with CRF, UCN 1, UCN 2 or UCN 3 and/or antalarmin or astressin 2B, selective antagonists of CRF1 receptor and CRF2 receptor, respectively. The mice were investigated in a Crawley social interaction test arena consisting of three chambers: an unknown female was set in the first chamber and a known female, with which the male was familiarized previously for 24h, was set in the third chamber. First the tested male was habituated with the middle chamber for 5min and then allowed to explore the remaining chambers for 5min, during which the number of entries and the time of interaction were measured. CRF decreased significantly the number of entries and the time of interaction with the unknown female, but not the known female. UCN 1 decreased significantly the number of entries into the chamber of the unknown female, but not the known female, without changing the time of interaction. All decreasing effects were reversed by antalarmin, but not astressin 2B. UCN 2 and UCN 3 didn't influence significantly any of the parameters. The present study suggests that CRF and UCN 1 decrease the preference for social novelty by activating CRF1 receptor, while UCN 2 and UCN 3, activating selectively CRF2 receptor, do not participate to male-female interaction., (Copyright © 2017 Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
228. Antiamnesic properties of analogs and mimetics of the tripeptide human urocortin 3.
- Author
-
Telegdy G, Kovács AK, Rákosi K, Zarándi M, and Tóth GK
- Subjects
- Amnesia metabolism, Amnesia pathology, Amnesia physiopathology, Animals, Female, Humans, Mice, Amnesia drug therapy, Corticotropin-Releasing Hormone chemistry, Oligopeptides chemical synthesis, Oligopeptides chemistry, Oligopeptides pharmacology, Peptidomimetics chemical synthesis, Peptidomimetics chemistry, Peptidomimetics pharmacology, Urocortins chemistry
- Abstract
Amnesia is a deficit in memory caused by brain damage, disease, or trauma. Until now, there are no successful medications on the drug market available to treat amnesia. Short analogs and mimetics of human urocortin 3 (Ucn 3) tripeptide were synthetized and tested for their action against amnesia induced by eletroconvulsion in mice. Among the 16 investigated derivatives of Ucn 3 tripeptide, eight compounds displayed antiamnesic effect. Our results proved that the configuration of chiral center of glutamine does not affect the antiamnesic properties. Alkyl amide or isoleucyl amide at the C-terminus may lead to antiamnesic compounds. As concerned the N-terminus, acetyl, Boc, and alkyl ureido moieties were found among the active analogs, but the free amino function at the N-terminus usually led to an inactive derivatives. These observations may lead to the design and synthesis of small peptidomimetics and amino acid derivatives as antiamnesic drug candidates, although the elucidation of the mechanism of the action requires further investigations.
- Published
- 2016
- Full Text
- View/download PDF
229. Anxiolytic effect of the GPR103 receptor agonist peptide P550 (homolog of neuropeptide 26RFa) in mice. Involvement of neurotransmitters.
- Author
-
Palotai M and Telegdy G
- Subjects
- Animals, Anxiety drug therapy, Atropine pharmacology, Bicuculline pharmacology, Cyproheptadine pharmacology, Haloperidol pharmacology, Methysergide pharmacology, Mice, Neuropeptides pharmacology, Neurotransmitter Agents metabolism, Neurotransmitter Agents pharmacology, Phenoxybenzamine pharmacology, Propranolol pharmacology, Receptors, G-Protein-Coupled agonists, Anxiety metabolism, Neuropeptides metabolism, Receptors, G-Protein-Coupled metabolism, Receptors, GABA-A metabolism
- Abstract
The GPR103 receptor is a G protein-coupled receptor, which plays a role in several physiological functions. However, the role of the GPR103 receptor in anxiety has not been clarified. The first aim of our study was to elucidate the involvement of the GPR103 receptor in anxious behavior. Mice were treated with peptide P550, which is the mouse homolog of neuropeptide 26RFa and has similar activity for the GPR103 receptor as neuropeptide 26RFa. The anxious behavior was investigated using an elevated plus-maze paradigm. The second aim of our study was to investigate the underlying neurotransmissions. Accordingly, mice were pretreated with a nonselective muscarinic acetylcholine receptor antagonist, atropine, a γ-aminobutyric acid subunit A (GABAA) receptor antagonist, bicuculline, a non-selective 5-HT2 serotonergic receptor antagonist, cyproheptadine, a mixed 5-HT1/5-HT2 serotonergic receptor antagonist, methysergide, a D2, D3, D4 dopamine receptor antagonist, haloperidol, a nonselective α-adrenergic receptor antagonist, phenoxybenzamine and a nonselective β-adrenergic receptor antagonist, propranolol. Our results demonstrated that peptide P550 reduces anxious behavior in elevated plus maze test in mice. Our study shows also that GABAA-ergic, α- and β-adrenergic transmissions are all involved in this action, whereas 5-HT1 and 5-HT2 serotonergic, muscarinic cholinergic and D2, D3, D4 dopaminergic mechanisms may not be implicated., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
230. The action of neuropeptide AF on passive avoidance learning. Involvement of neurotransmitters.
- Author
-
Palotai M, Telegdy G, Bagosi Z, and Jászberényi M
- Subjects
- Amyloid beta-Peptides administration & dosage, Animals, Avoidance Learning drug effects, Male, Memory Consolidation drug effects, Mice, Neurotransmitter Agents administration & dosage, Oligopeptides administration & dosage, Avoidance Learning physiology, Memory Consolidation physiology, Oligopeptides physiology
- Abstract
Neuropeptide AF (NPAF) is an amidated octadecapeptide, which is member of the RFamide peptide family. NPAF is encoded by the farp-1 gene and acts through the G protein coupled NPFF-1 and NPFF-2 receptors. NPAF is involved in several physiological functions of the central nervous system, however we have little evidence about the involvement of NPAF in learning and memory. Therefore, the aim of the present study was to investigate the action of NPAF on consolidation of memory in a passive avoidance learning paradigm in mice. We have also investigated the underlying neurotransmissions and the action of NPAF on β-amyloid-induced memory impairment. Accordingly, mice were pretreated with a nonselective muscarinic acetylcholine receptor antagonist, atropine, a non-selective 5-HT2 serotonergic receptor antagonist, cyproheptadine, a mixed 5-HT1/5-HT2 serotonergic receptor antagonist, methysergide, a D2, D3, D4 dopamine receptor antagonist, haloperidol, a non-selective opioid receptor antagonist, naloxone, a nitric oxide synthase inhibitor, nitro-l-arginine, a α1/α2β-adrenergic receptor antagonist, prazosin, a nonselective β-adrenergic receptor antagonist, propranolol or β-amyloid 25-35 in combination with NPAF administration. Our results demonstrate for the first time that NPAF improves the consolidation of passive avoidance learning. This effect is mediated through muscarinic cholinergic, 5HT1- and 5HT2-serotoninergic, dopaminergic, nitrergic and α- and β-adrenergic neurotransmissions, but not by opioid transmission, since atropine, cyproheptadine, methysergide, haloperidol, nitro-l-arginine, prazosin and propranolol reversed the action of NPAF, whereas naloxone was ineffective. The present study also shows that NPAF reverses the β-amyloid 25-35-induced memory impairment., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
231. The effects of CRF and urocortins on the hippocampal glutamate release.
- Author
-
Bagosi Z, Balangó B, Pintér D, Csabafi K, Jászberényi M, Szabó G, and Telegdy G
- Subjects
- Amygdala drug effects, Animals, Hippocampus drug effects, Hypothalamus metabolism, Male, Rats, Wistar, Corticotropin-Releasing Hormone pharmacology, Glutamic Acid metabolism, Hypothalamo-Hypophyseal System drug effects, Hypothalamus drug effects, Pituitary-Adrenal System drug effects, Urocortins pharmacology
- Abstract
Corticotropin-releasing factor (CRF) is a hypothalamic neurohormone and an extrahypothalamic neurotransmitter that regulates the hypothalamic-pituitary-adrenal (HPA) axis. The urocortins (UCN I, UCN II and UCN III) are CRF-related peptides, which may also regulate the HPA axis directly or indirectly, by modulation of extrahypothalamic neurotransmitters, such as amygdalar GABA and hippocampal glutamate. Our previous in vitro superfusion studies have already demonstrated that CRF and UCN I stimulate the amygdalar GABA release in rats. The aim of the present study was to investigate the effects of CRF, UCN I, UCN II and UCN III on the glutamate release elicited electrically from rat hippocampal slices in similar in vitro conditions. In order to investigate the participation of CRF receptors (CRFR1 and CRFR2) in this process, hippocampal slices were pretreated with antalarmin, a selective antagonist of CRFR1 or astressin 2B, a selective antagonist of CRFR2. CRF and UCN I at 100 nM decreased significantly the hippocampal glutamate release evoked by electrical stimulation. In contrast, 100 nM of UCN II and UCN III did not affect significantly the hippocampal glutamate release enhanced by electrical stimulation. The decreasing effects of CRF and UCN I were reversed by antalarmin, but not by astressin 2B, both being administered in equimolar doses. Our results demonstrate that CRF and UCN I inhibit the glutamate release in the hippocampus via CRFR1 and that CRFR2 does not participate to this process. Based on the previous and the present results we conclude that CRFR1 agonists can activate the HPA axis not only directly, but also indirectly by increasing the amygdalar GABA release and decreasing the hippocampal glutamate release., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
232. The effect of kisspeptin on the regulation of vascular tone.
- Author
-
Mezei Z, Zamani-Forooshani O, Csabafi K, Szikszai B, Papp E, Ónodi Á, Török D, Leprán Á, Telegdy G, and Szabó G
- Subjects
- 6-Ketoprostaglandin F1 alpha biosynthesis, Animals, Aorta drug effects, Aorta metabolism, Arachidonic Acid metabolism, Blood Platelets drug effects, Blood Platelets metabolism, Dose-Response Relationship, Drug, Kisspeptins pharmacology, Male, Rats, Signal Transduction drug effects, Signal Transduction physiology, Thromboxanes biosynthesis, Eicosanoids biosynthesis, Kisspeptins physiology, Vasoconstriction physiology
- Abstract
Kisspeptin has been implicated in cardiovascular control. Eicosanoids play a crucial role in the activation of platelets and the regulation of vascular tone. In the present study, we investigated the effect of kisspeptins on eicosanoid synthesis in platelets and aorta in vitro. Platelets and aorta were isolated from Wistar-Kyoto rats. After preincubation with different doses of kisspeptin, samples were incubated with [1-(14)C]arachidonic acid (0.172 pmol/mL) in tissue culture Medium 199. The amount of labeled eicosanoids was measured with liquid scintillation, after separation with overpressure thin-layer chromatography. Kisspeptin-13 stimulated the thromboxane synthesis. The dose-response curve was bell-shaped and the most effective concentration was 2.5 × 10(-8) mol/L, inducing a 27% increase. Lipoxygenase products of platelets displayed a dose-dependent elevation up to the dose of 5 × 10(-8) mol/L. In the aorta, kisspeptin-13 induced a marked elevation in the production of 6-keto-prostaglandin F1α, the stable metabolite of prostacyclin, and lipoxygenase products. Different effects of kisspeptin on cyclooxygenase and lipoxygenase products indicate that beyond intracellular Ca(2+) mobilization, other signaling pathways might also contribute to its actions. Our data suggest that kisspeptin, through the alteration of eicosanoid synthesis in platelets and aorta, may play a physiologic and (or) pathologic role in the regulation of vascular tone.
- Published
- 2015
- Full Text
- View/download PDF
233. Neurotransmitter-mediated anxiogenic action of PACAP-38 in rats.
- Author
-
Telegdy G and Adamik A
- Subjects
- Adrenergic Antagonists pharmacology, Adrenergic beta-Antagonists pharmacology, Animals, Arginine analogs & derivatives, Arginine pharmacology, Atropine pharmacology, Bicuculline pharmacology, Dopamine Antagonists pharmacology, Exploratory Behavior drug effects, Haloperidol pharmacology, Male, Maze Learning drug effects, Methysergide pharmacology, Muscarinic Antagonists pharmacology, Naloxone pharmacology, Narcotic Antagonists pharmacology, Nitroso Compounds pharmacology, Peptide Fragments metabolism, Peptide Fragments pharmacology, Phenoxybenzamine pharmacology, Pituitary Adenylate Cyclase-Activating Polypeptide metabolism, Propranolol pharmacology, Rats, Rats, Wistar, Receptors, GABA drug effects, Receptors, GABA metabolism, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide agonists, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide antagonists & inhibitors, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide classification, Serotonin 5-HT2 Receptor Antagonists pharmacology, Anxiety drug therapy, Anxiety metabolism, Neurotransmitter Agents metabolism, Neurotransmitter Agents pharmacology, Pituitary Adenylate Cyclase-Activating Polypeptide pharmacology, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide metabolism
- Abstract
The action of PACAP-38 was studied by measuring the anxiogenic-anxiolytic behavior of rats in an elevated plus maze. PACAP-38 was administered into the lateral brain ventricle and the behavior of the animals was measured 3h later. The possible involvement of transmitters was measured by pretreating the animals with receptor blockers which alone did not influence the task, but in the doses used were effective with other neuropeptides. The receptor antagonist PACAP 6-38 (a PAC 1/VPAC2 receptor antagonist of PACAP-38 receptor), haloperidol (a non-selective dopamine receptor antagonist), phenoxybenzamine (an α1/α2β-adrenergic receptor antagonist), propranolol(a β-adrenergic receptor antagonist), bicuculline (a gamma-aminobutyric acid subunit A receptor antagonist), methysergide (a nonselective 5-HT2 serotonergic receptor antagonist), atropine (a nonselective muscarinic acetylcholine receptor antagonist), naloxone (a nonselective opioid receptor antagonist) and nitro-l-arginine which acts by blocking the enzyme nitric oxide synthase, thereby blocking the nitric oxide synthesis, were tested. The following parameters were measured: the time spent in open arms/the time spent in total entries. PACAP-38 decreased the ratio of time spent in open arms to the time spent in total entries, indicating anxiogenic action. The total number of entries was not altered significantly either by PACAP-38 or by the receptor blockers. The following receptor blockers diminished the action of PACAP-38: PACAP 6-38,haloperidol, methysergide, naloxone and nitro-l-arginine. Pretreatment with atropine, phenoxybenzamine, propranolol and bicuculline did not influence the action of PACAP-38 on the time spent in open arms. The results demonstrate that PACAP-38 administered into the lateral brain ventricle exerted anxiogenic action at 3 h following treatment. Pretreatment of the animals with various receptor blockers indicated that a nonselective dopaminergic receptor antagonist, 5HT2 serotonergic and opioid receptors, nitric oxide and PAC1 receptors are involved in the anxiogenic action induced by PACAP-38., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
234. Short analogs and mimetics of human urocortin 3 display antidepressant effects in vivo.
- Author
-
Rákosi K, Masaru T, Zarándia M, Telegdy G, and Tóth GK
- Subjects
- Amino Acid Sequence, Animals, Antidepressive Agents chemical synthesis, Behavior, Animal drug effects, Corticotropin-Releasing Hormone chemical synthesis, Depressive Disorder pathology, Humans, Mice, Peptides chemical synthesis, Peptidomimetics administration & dosage, Peptidomimetics chemical synthesis, Urocortins chemical synthesis, Antidepressive Agents administration & dosage, Corticotropin-Releasing Hormone administration & dosage, Depressive Disorder drug therapy, Peptides administration & dosage, Urocortins administration & dosage
- Abstract
Peptide analogs of urocortin 3[36–38] (Ucn 3[36–38]), obtained with deletion or replacement of amino acids of the original human urocortin 3 sequence, were designed, synthesized, and tested in vivo for treatment of depression. Based on the results of the biological tests of the peptide analogs, several new peptidomimetics of the above short analogs of urocortin 3, including urea- and azapeptides, were also designed and synthesized and found to preserve the antidepressant-like effect of the 38 amino acid long original neuropeptide. The molecular modifications of urocortin 3[36–38] led to an improved understanding of the relationship between molecular structure and biological activity of this peptide, and the novel peptidomimetics could be further tested for possible clinical treatment of depression.
- Published
- 2014
- Full Text
- View/download PDF
235. Neuropeptide AF induces anxiety-like and antidepressant-like behavior in mice.
- Author
-
Palotai M, Telegdy G, Tanaka M, Bagosi Z, and Jászberényi M
- Subjects
- Adrenergic alpha-1 Receptor Antagonists pharmacology, Adrenergic alpha-Antagonists pharmacology, Animals, Disease Models, Animal, Dopamine Antagonists pharmacology, Dose-Response Relationship, Drug, Haloperidol pharmacology, Immobility Response, Tonic drug effects, Male, Maze Learning drug effects, Mice, Phenoxybenzamine pharmacology, Prazosin pharmacology, Serotonin Agents pharmacology, Swimming psychology, Antidepressive Agents therapeutic use, Antidepressive Agents toxicity, Anxiety chemically induced, Oligopeptides therapeutic use, Oligopeptides toxicity
- Abstract
Little is known about the action of neuropeptide AF (NPAF) on anxiety and depression. Only our previous study provides evidence that NPAF induces anxiety-like behavior in rats. Therefore, the aim of the present study was to investigate the action of NPAF on depression-like behavior and the underlying neurotransmissions in mice. In order to determine whether there are species differences between rats and mice, we have investigated the action of NPAF on anxiety-like behavior in mice as well. A modified forced swimming test (mFST) and an elevated plus maze test (EPMT) were used to investigate the depression and anxiety-related behaviors, respectively. Mice were treated with NPAF 30min prior to the tests. In the mFST, the animals were pretreated with a non-selective muscarinic acetylcholine receptor antagonist, atropine, a non-selective 5-HT2 serotonergic receptor antagonist, cyproheptadine, a mixed 5-HT1/5-HT2 serotonergic receptor antagonist, methysergide, a D2/D3/D4 dopamine receptor antagonist, haloperidol, a α1/α2β-adrenergic receptor antagonist, prazosin or a non-selective β-adrenergic receptor antagonist, propranolol 30min before the NPAF administration. In the mFST, NPAF decreased the immobility time and increased the climbing and swimming times. This action was reversed completely by methysergide and partially by atropine, whereas cyproheptadine, haloperidol, prazosin and propranolol were ineffective. In the EPMT, NPAF decreased the time spent in the arms (open/open+closed). Our results demonstrate that NPAF induces anti-depressant-like behavior in mice, which is mediated, at least in part, through 5HT2-serotonergic and muscarinic cholinergic neurotransmissions. In addition, the NPAF-induced anxiety is species-independent, since it develops also in mice., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
236. The action of orexin B on passive avoidance learning. Involvement of neurotransmitters.
- Author
-
Palotai M, Telegdy G, Ekwerike A, and Jászberényi M
- Subjects
- Adrenergic Antagonists pharmacology, Animals, Avoidance Learning drug effects, Dopamine Antagonists pharmacology, GABA-A Receptor Antagonists pharmacology, Male, Memory drug effects, Memory physiology, Narcotic Antagonists pharmacology, Nitric Oxide Synthase antagonists & inhibitors, Nitric Oxide Synthase metabolism, Orexin Receptor Antagonists, Orexin Receptors metabolism, Orexins, Rats, Wistar, Receptors, Adrenergic, alpha metabolism, Receptors, Adrenergic, beta metabolism, Receptors, Dopamine D2 metabolism, Receptors, Dopamine D3 metabolism, Receptors, Dopamine D4 metabolism, Receptors, GABA-A metabolism, Receptors, Opioid metabolism, Synaptic Transmission drug effects, Synaptic Transmission physiology, Avoidance Learning physiology, Intracellular Signaling Peptides and Proteins metabolism, Neuropeptides metabolism, Neurotransmitter Agents metabolism
- Abstract
The extensive projection of orexigenic neurons and the diffuse expression of orexin receptors suggest that endogenous orexins are involved in several physiological functions of the central nervous system, including learning and memory. Our previous study demonstrated that orexin A improves learning, consolidation and retrieval processes, which involves α- and β-adrenergic, cholinergic, dopaminergic, GABA-A-ergic, opiate and nitrergic neurotransmissions. However, we have little evidence about the action of orexin B on memory processes and the underlying neuromodulation. Therefore, the aim of the present study was to investigate the action of orexin B on passive avoidance learning and the involvement of neurotransmitters in this action in rats. Accordingly, rats were pretreated with the selective orexin 2 receptor (OX2R) antagonist, EMPA; the γ-aminobutyric acid subunit A (GABA-A) receptor antagonist, the bicuculline; a D2, D3, D4 dopamine receptor antagonist, haloperidol; the nonselective opioid receptor antagonist, naloxone; the non-specific nitric oxide synthase (NOS) inhibitor, nitro-l-arginine; the nonselective α-adrenergic receptor antagonist, phenoxybenzamine and the β-adrenergic receptor antagonist, propranolol. Our results demonstrate that orexin B can improve learning, consolidation of memory and retrieval. EMPA reversed completely the action of orexin B on memory consolidation. Bicuculline blocked fully; naloxone, nitro-l-arginine, phenoxybenzamine and propranolol attenuated the orexin B-induced memory consolidation, whereas haloperidol was ineffective. These data suggest that orexin B improves memory functions through OX2R and GABA-ergic, opiate, nitrergic, α- and β-adrenergic neurotransmissions are also involved in this action., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
237. Urocortin 3 administration impairs fear motivated learning in mice is mediated by transmitters.
- Author
-
Telegdy G, Foris L, and Jászberényi M
- Subjects
- Adrenergic alpha-Antagonists pharmacology, Animals, Arginine pharmacology, Atropine pharmacology, Bicuculline pharmacology, Corticotropin-Releasing Hormone administration & dosage, Corticotropin-Releasing Hormone antagonists & inhibitors, Dopamine Antagonists pharmacology, GABA-A Receptor Antagonists pharmacology, Haloperidol pharmacology, Male, Mice, Mice, Inbred Strains, Muscarinic Antagonists pharmacology, Peptide Fragments pharmacology, Phenoxybenzamine pharmacology, Pyrimidines pharmacology, Pyrroles pharmacology, Urocortins administration & dosage, Avoidance Learning drug effects, Corticotropin-Releasing Hormone pharmacology, Fear drug effects, Memory drug effects, Motivation drug effects, Urocortins pharmacology
- Abstract
Urocortin 3 (Ucn 3) was found to impair passive avoidance learning in male and female mice. The possible involvement of transmitters in the action, the animals were pretreated with the following receptor antagonists in doses which alone could not influence the measurement. Haloperidol (a D2, dopamine receptor antagonist), phenoxybenzamine (a nonselective α1-adrenergic receptor antagonist), atropine (a nonselective muscarinic acetylcholine receptor antagonist), bicuculline (a γ-aminobutyric acid subunit A receptor antagonist), nitro-L-arginine (a nitric oxide synthase inhibitor), antalarmin (a CRF1 receptor antagonist) and astressin 2B (a CRF2 receptor antagonist). Haloperidol, phenoxybenzamine, bicuculline, atropine, nitro-L-arginine and astressin 2B prevented the action of Ucn 3, in both sexes, whereas antalarmin exerted no action in either male or female animals., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
238. Involvement of neurotransmitters in the action of the nociceptin/orphanin FQ peptide-receptor system on passive avoidance learning in rats.
- Author
-
Palotai M, Adamik A, and Telegdy G
- Subjects
- Animals, Dose-Response Relationship, Drug, Male, Opioid Peptides pharmacology, Rats, Rats, Wistar, Nociceptin Receptor, Nociceptin, Avoidance Learning drug effects, Avoidance Learning physiology, Neurotransmitter Agents metabolism, Opioid Peptides metabolism, Receptors, Opioid agonists, Receptors, Opioid metabolism
- Abstract
The nociceptin/orphanin FQ peptide (NOP) receptor and its endogenous ligand plays role in several physiologic functions of the central nervous system, including pain, locomotion, anxiety and depression, reward and drug addiction, learning and memory. Previous studies demonstrated that the NOP-receptor system induces impairment in memory and learning. However, we have little evidence about the underlying neuromodulation. The aim of the present study was to investigate the involvement of distinct neurotransmitters in the action of the selective NOP receptor agonist orphan G protein-coupled receptor (GPCR) SP9155 P550 on memory consolidation in a passive avoidance learning test in rats. Accordingly, rats were pretreated with a nonselective muscarinic acetylcholine receptor antagonist, atropine, a γ-aminobutyric acid subunit A (GABA-A) receptor antagonist, bicuculline, a D2, D3, D4 dopamine receptor antagonist, haloperidol, a nonselective opioid receptor antagonist, naloxone, a non-specific nitric oxide synthase inhibitor, nitro-L-arginine, a nonselective α-adrenergic receptor antagonist, phenoxybenzamine and a β-adrenergic receptor antagonist, propranolol. Atropine, bicuculline, naloxone and phenoxybenzamine reversed the orphan GPCR SP9155 P550-induced memory impairment, whereas propranolol, haloperidol and nitro-L-arginine were ineffective. Our results suggest that the NOP system-induced impairment of memory consolidation is mediated through muscarinic cholinergic, GABA-A-ergic, opioid and α-adrenergic receptors, whereas β-adrenergic, D2, D3, D4-dopaminergic and nitrergic mechanisms are not be implicated.
- Published
- 2014
- Full Text
- View/download PDF
239. Orexin A-induced anxiety-like behavior is mediated through GABA-ergic, α- and β-adrenergic neurotransmissions in mice.
- Author
-
Palotai M, Telegdy G, and Jászberényi M
- Subjects
- Animals, Anxiety chemically induced, Anxiety metabolism, Atropine administration & dosage, Bicuculline administration & dosage, Haloperidol administration & dosage, Mice, Neurotransmitter Agents administration & dosage, Orexins, Phenoxybenzamine administration & dosage, Propranolol administration & dosage, Anxiety physiopathology, Behavior, Animal drug effects, Intracellular Signaling Peptides and Proteins administration & dosage, Neuropeptides administration & dosage, gamma-Aminobutyric Acid metabolism
- Abstract
Orexins are hypothalamic neuropeptides, which are involved in several physiological functions of the central nervous system, including anxiety and stress. Several studies provide biochemical and behavioral evidence about the anxiogenic action of orexin A. However, we have little evidence about the underlying neuromodulation. Therefore, the aim of the present study was to investigate the involvement of neurotransmitters in the orexin A-induced anxiety-like behavior in elevated plus maze (EPM) test in mice. Accordingly, mice were pretreated with a non-selective muscarinic cholinergic antagonist, atropine; a γ-aminobutyric acid subunit A (GABA-A) receptor antagonist, bicuculline; a D2, D3, D4 dopamine receptor antagonist, haloperidol; a non-specific nitric oxide synthase (NOS) inhibitor, nitro-l-arginine; a nonselective α-adrenergic receptor antagonist, phenoxybenzamine and a β-adrenergic receptor antagonist, propranolol 30min prior to the intracerebroventricular administration of orexin A. The EPM test started 30min after the i.c.v. injection of the neuropeptide. Our results show that orexin A decreases significantly the time spent in the arms (open/open+closed) and this action is reversed by bicuculline, phenoxybenzamine and propranolol, but not by atropine, haloperidol or nitro-l-arginine. Our results provide evidence for the first time that the orexin A-induced anxiety-like behavior is mediated through GABA-A-ergic, α- and β-adrenergic neurotransmissions, whereas muscarinic cholinergic, dopaminergic and nitrergic neurotransmissions may not be implicated., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
240. Mediators involved in the hyperthermic action of neuromedin U in rats.
- Author
-
Telegdy G and Adamik A
- Subjects
- Animals, Male, Rats, Rats, Wistar, Neuropeptides metabolism, Temperature
- Abstract
Neuromedin U (NmU), first was isolated from the porcine spinal cord, has subsequently been demonstrated in a number of species, in which it is present in the periphery and also the brain. Two receptors have been identified: NmU1R is mainly present in peripheral tissues, and Nmu2R in the central nervous system. NmU, a potent endogenous anorectic, serves as a catabolic signaling molecule in the brain; it inhibits food uptake, increases locomotion, activates stress mechanism, having cardiovasscular effects and, causes hyperthermia. The mechanism of this hyperthermia is unknown. In the present experiments, the effects of NmU on the colon temperature following i.c.v administration were studied in rats. For an investigation of the possible role of receptors in mediating hyperthermia, the animals were treated simultaneously with CRF 9-41 and antalarmin, a CRH1 receptor inhibitors, astressin 2B, a CRH2 receptor antagonist, haloperidol a dopamine receptor antagonist, atropine a muscarinic cholinergic receptor antagonist, noraminophenazone a cyclooxygenase inhibitor or isatin, a prostaglandin receptor antagonist. NmU increased the colon temperature, maximal action being observed at 2-3h. CRF 9-41, antalarmin, astressin 2B haloperidol, atropine, noraminophenazone and isatin prevented the NmU-induced increase in colon temperature. The results demonstrated that, when injected into the lateral brain ventricle NmU increased the body temperature, mediated by CRHR1 and CRHR2, dopamine and muscarinic cholinergic receptors. The final pathway involves prostaglandin., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
241. Transmitter mediation of the anxiolytic action of apelin-13 in male mice.
- Author
-
Telegdy G and Jászberényi M
- Subjects
- Adrenergic alpha-Antagonists pharmacology, Adrenergic beta-Antagonists pharmacology, Animals, Anxiety drug therapy, Atropine pharmacology, Bicuculline pharmacology, Dopamine Antagonists pharmacology, GABA-A Receptor Antagonists pharmacology, Haloperidol pharmacology, Male, Maze Learning drug effects, Methysergide pharmacology, Mice, Muscarinic Antagonists pharmacology, Naloxone pharmacology, Narcotic Antagonists pharmacology, Phenoxybenzamine pharmacology, Propranolol pharmacology, Receptors, Neurotransmitter metabolism, Serotonin Antagonists pharmacology, Anxiety physiopathology, Intercellular Signaling Peptides and Proteins administration & dosage, Intercellular Signaling Peptides and Proteins metabolism, Maze Learning physiology
- Abstract
The widespread distribution of apelin-13 and apelin receptors in the brain and periphery suggests an important function of this neuropeptide in regulatory processes in the organism. In previous work we found that apelin-13 facilitates the consolidation of passive avoidance learning in rats. In the present work we demonstrate that apelin-13 exerts anxiolytic action in an elevated plus maze in mice. In order to assess the possible involvement of transmitters in this action, the animals were pretreated with the following receptor blockers in doses which themselves did not influence the behavioral paradigm: atropine (a nonselective muscarinic acetylcholine receptor antagonist), haloperidol (a D2, D3, D4 dopamine receptor antagonist), phenoxybenzamine (a nonselective α1-adrenergic receptor antagonist), methysergide (a nonselective 5-HT2 serotonergic receptor antagonist), propranolol (a β-adrenergic receptor antagonist), naloxone (a nonselective opioid receptor antagonist) and bicuculline (a γ-aminobutyric acid subunit A receptor antagonist. Phenoxybenzamine, haloperidol, propranolol and methysergide prevented the action of apelin-13, whereas atropine, naloxone and bicuculline were ineffective. The data suggest that apelin-13 elicits its anxiolytic action via α-adrenergic, dopaminergic, β-adrenergic and 5-HT2 serotonergic mediation., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
242. Interleukin-1β (187-207)-induced hyperthermia is inhibited by interleukin-1β (193-195) in rats.
- Author
-
Palotai M, Kiss E, Bagosi Z, Jászberényi M, Tóth G, Váradi G, and Telegdy G
- Subjects
- Amino Acid Sequence, Animals, Body Temperature, Injections, Intraventricular, Interleukin-1beta administration & dosage, Interleukin-1beta chemistry, Male, Molecular Sequence Data, Peptide Fragments administration & dosage, Peptide Fragments chemistry, Rats, Rats, Wistar, Fever chemically induced, Interleukin-1beta pharmacology, Peptide Fragments pharmacology
- Abstract
Interleukin-1β (IL-1β) is a pro-inflammatory cytokine, which plays an important role in the immune response and signal transduction both in the periphery and the central nervous system (CNS). Various diseases of the CNS, including neurodegenerative disorders, vascular lesions, meningo-encephalitis or status epilepticus are accompanied by elevated levels of IL-1β. Different domains within the IL-lβ protein are responsible for distinct functions. The IL-lβ domain in position 208-240 has pyrogenic properties, while the domain in position 193-195 exerts anti-inflammatory effects. Previous studies provide little evidence about the effect of the domain in position 187-207 on the body temperature. Therefore, the aim of the present study was to investigate the action of IL-1β (187-207) and its interaction with IL-1β (193-195) on the body temperature. IL fragments were administered intracerebroventricularly and the body temperature was measured rectally in male Wistar rats. IL-1β (187-207) induced hyperthermia, while IL-1β (193-195) did not influence the core temperature considerably. In co-administration, IL-1β (193-195) completely abolished the IL-1β (187-207)-induced hyperthermia. The non-steroid anti-inflammatory drug metamizole also reversed completely the action of IL-1β (187-207). Our results provide evidence that the IL-lβ domain in position 187-207 has hyperthermic effect. This effect is mediated through prostaglandin E2 stimulation and other mechanisms may also be involved in the action of IL-1β (187-207). It also suggests that IL-lβ domain in position 187-207 and IL-1β (193-195) fragment may serve as novel target for treatment of disorders accompanied with hyperthermia.
- Published
- 2014
- Full Text
- View/download PDF
243. The effect of urocortin I on the hypothalamic ACTH secretagogues and its impact on the hypothalamic-pituitary-adrenal axis.
- Author
-
Bagosi Z, Csabafi K, Palotai M, Jászberényi M, Földesi I, Gardi J, Szabó G, and Telegdy G
- Subjects
- Animals, Arginine Vasopressin analysis, Corticotropin-Releasing Hormone analysis, Hypothalamo-Hypophyseal System drug effects, Hypothalamus drug effects, Male, Pituitary-Adrenal System drug effects, Rats, Rats, Wistar, Adrenocorticotropic Hormone blood, Corticosterone blood, Hypothalamus metabolism, Urocortins pharmacology
- Abstract
Urocortin I (UCN I) is a structural analogue of corticotropin-releasing factor (CRF), which, together with arginine-vasopressin (AVP), are the principle adrenocorticotropic hormone (ACTH) secretagogues in mammals. The aim of the present study was to investigate the effects of UCN I on the hypothalamic CRF and AVP concentration and its impact on the hypothalamic-pituitary-adrenal (HPA) axis. First, male Wistar rats were injected intracerebroventricularly (ICV) with 0.5, 1, 2 and 5 μg of UCN I. After 30 min hypothalamic CRF and AVP concentrations were determined by immunoassays. In parallel, the trunk blood was collected and plasma ACTH and corticosterone concentration was determined by ELISA and chemofluorescent assay, respectively. Second, rats were pretreated ICV with selective antagonists of receptors being implicated in the regulation of the HPA axis (0.1 μg antalarmin for CRFR1, 1 μg astressin 2B for CRFR2 or 0.1 μg deamino-Pen1,Tyr2,Arg8-vasopressin for AVPR3) and treated ICV with the most effective dose of UCN I (5 μg). After 30 min plasma corticosterone concentration was determined by chemofluorescent assay. UCN I induced dose-dependent augmentation of the hypothalamic CRF and AVP concentration, associated with dose-dependent elevation of the plasma ACTH and corticosterone concentration. The most significant effect of UCN I on the plasma corticosterone concentration was inhibited by antalarmin, but was not influenced by astressin 2B or deamino-Pen1,Tyr2,Arg8-vasopressin. The present study demonstrates that UCN I modulates the concentration of the hypothalamic ACTH secretagogues in parallel with the concentration of the plasma ACTH and corticosterone. Our results suggest that UCN I may activate the HPA axis by stimulation of the hypothalamic CRF production, and this process is mediated by CRFR1, and not by CRFR2. UCN I may stimulate the AVP production, as well, but, based on the results with AVPR3 antagonist, this effect is not involved in the regulation of the HPA axis., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
244. Neurotransmissions of antidepressant-like effects of neuromedin U-23 in mice.
- Author
-
Tanaka M and Telegdy G
- Subjects
- Analysis of Variance, Animals, Atropine pharmacology, Bicuculline pharmacology, Disease Models, Animal, Freezing Reaction, Cataleptic drug effects, GABA-A Receptor Antagonists pharmacology, Male, Methysergide pharmacology, Mice, Muscarinic Antagonists pharmacology, Serotonin Antagonists pharmacology, Swimming psychology, Antidepressive Agents therapeutic use, Depression drug therapy, Neuropeptides therapeutic use, Synaptic Transmission drug effects
- Abstract
Neuromedin U (NmU) is a widely distributed and multifunctional peptide in the central nervous system and the peripheral tissues. Little is know about the mechanisms of NmU on brain functions. The rodent isoform of the NmU, NmU-23, has been shown to have anxiolytic effects involved in the β-adrenergic and cholinergic nervous systems in elevated plus maze test. NmU-23 was tested for antidepressant-like effects in modified forced swimming test (FST) in mice and furthermore, the involvement of the adrenergic, serotonergic, cholinergic, dopaminergic or gaba-ergic receptors in the antidepressant-like effect of NmU-23 was studied in modified mice FST. Mice were pretreated with a non-selective α-adrenergic receptor antagonist phenoxybenzamine, an α1/α2β-adrenergic receptor antagonist, prazosin, an α2-adrenergic receptor antagonist, yohimbine, a β-adrenergic receptor antagonist, propranolol, a mixed 5-HT1/5-HT2 serotonergic receptor antagonist, methysergide, a non-selective 5-HT2 serotonergic receptor antagonist, cyproheptadine, nonselective muscarinic acetylcholine receptor antagonist, atropine, D2,D3,D4 dopamine receptor antagonist, haloperidol or γ-aminobutyric acid subunit A (GABAA) receptor antagonist, bicuculline. NmU-23 showed the antidepressant-like effects by decreasing the immobility time and increasing the climbing and swimming time. Prazosin, haloperidol, and bicuculline prevented the effects of NmU-23 on the climbing and swimming time. Methysergide and cyproheptadine prevented the effects of NmU-23 on the immobility, swimming and climbing time. Atropine prevented the effects of NmU-23 on the climbing time. Phenoxybenzamine, yohimbine and propranolol did not change the effects of NmU-23. The results demonstrated that the antidepressant-like effect of NmU-23 is mediated, at least in part, by an interaction of the α2-adrenergic, 5-HT1-2 serotonergic, D2,D3,D4 dopamine receptor, muscarinic acetylcholine receptors and γ-aminobutyric acid subunit A (GABAA) receptor in a modified mouse FST., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
245. The actions of neuropeptide SF on the hypothalamic-pituitary-adrenal axis and behavior in rats.
- Author
-
Jászberényi M, Bagosi Z, Csabafi K, Palotai M, and Telegdy G
- Subjects
- Adrenocorticotropic Hormone blood, Animals, Body Temperature Regulation, Corticosterone blood, Corticotropin-Releasing Hormone metabolism, Eliminative Behavior, Animal, Locomotion, Male, Neuropeptides pharmacology, Rats, Rats, Wistar, Hypothalamo-Hypophyseal System metabolism, Neuropeptides physiology, Pituitary-Adrenal System metabolism
- Abstract
Present experiments focused on measuring the effect of neuropeptide SF (NPSF) on the hypothalamus-pituitary-adrenal (HPA) axis and behavior. The peptide was administered in different doses (0.25, 0.5, 1, 2 μg) intracerebroventricularly to rats, and the behavior of which was then observed by telemetry and open-field test. Effect of NPSF on core temperature was also measured via telemetry. Plasma ACTH and corticosterone concentrations were measured to assess the influence of NPSF on the HPA activation. In addition, the changes in corticotrophin-releasing hormone (CRH) level in the hypothalamic paraventricular nucleus were continuously monitored by means of intracerebral microdialysis. Our results showed that NPSF augmented paraventricular CRH release and increased ACTH and corticosterone levels in the plasma. The release of corticosterone was successfully blocked by the pre-treatment of the CRH antagonist α-helical CRH9-41. Spontaneous and exploratory locomotor activity was also stimulated according to the telemetric and open-field studies. However, NPSF only tended to alter stereotyped behavior in the open-field experiments. These results demonstrate that NPSF may play a physiologic role in the regulation of such circadian functions as the activity of motor centers and the HPA axis, through the release of CRH., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
246. Ghrelin amplifies the nicotine-induced dopamine release in the rat striatum.
- Author
-
Palotai M, Bagosi Z, Jászberényi M, Csabafi K, Dochnal R, Manczinger M, Telegdy G, and Szabó G
- Subjects
- Animals, Corpus Striatum metabolism, Male, Rats, Rats, Wistar, Corpus Striatum drug effects, Dopamine metabolism, Ghrelin pharmacology, Nicotine pharmacology
- Abstract
The orexigenic peptide ghrelin plays a prominent role in the regulation of energy balance and in the mediation of reward mechanisms and reinforcement for addictive drugs, such as nicotine. Nicotine is the principal psychoactive component in tobacco, which is responsible for addiction and relapse of smokers. Nicotine activates the mesencephalic dopaminergic neurons via nicotinic acetylcholine receptors (nAchR). Ghrelin stimulates the dopaminergic neurons via growth hormone secretagogue receptors (GHS-R1A) in the ventral tegmental area and the substantia nigra pars compacta resulting in the release of dopamine in the ventral and dorsal striatum, respectively. In the present study an in vitro superfusion of rat striatal slices was performed, in order to investigate the direct action of ghrelin on the striatal dopamine release and the interaction of ghrelin with nicotine through this neurotransmitter release. Ghrelin increased significantly the dopamine release from the rat striatum following electrical stimulation. This stimulatory effect was reversed by both the selective nAchR antagonist mecamylamine and the selective GHS-R1A antagonist GHRP-6. Nicotine also increased significantly the dopamine release under the same conditions. This stimulatory effect was antagonized by mecamylamine, but not by GHRP-6. Ghrelin further stimulated the nicotine-induced dopamine release and this effect was abolished by mecamylamine and was partially inhibited by GHRP-6. The present results demonstrate that ghrelin stimulates directly the dopamine release and amplifies the nicotine-induced dopamine release in the rat striatum. We presume that striatal cholinergic interneurons also express GHS-R1A, through which ghrelin can amplify the nicotine-induced dopamine release in the striatum. This study provides further evidence of the impact of ghrelin on the mesolimbic and nigrostriatal dopaminergic pathways. It also suggests that ghrelin signaling may serve as a novel pharmacological target for treatment of addictive and neurodegenerative disorders., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
247. Ghrelin and nicotine stimulate equally the dopamine release in the rat amygdala.
- Author
-
Palotai M, Bagosi Z, Jászberényi M, Csabafi K, Dochnal R, Manczinger M, Telegdy G, and Szabó G
- Subjects
- Amygdala drug effects, Animals, In Vitro Techniques, Male, Mecamylamine, Oligopeptides pharmacology, Prefrontal Cortex metabolism, Rats, Rats, Wistar, Receptors, Ghrelin drug effects, Receptors, Nicotinic drug effects, Amygdala metabolism, Dopamine metabolism, Ghrelin pharmacology, Nicotine pharmacology
- Abstract
The orexigenic peptide ghrelin plays a prominent role in the regulation of energy balance and in the mediation of reward processes and reinforcement for addictive drugs, such as nicotine. Nicotine is the principal psychoactive component in tobacco, which is responsible for addiction and relapse of smokers. Ghrelin and nicotine activates the mesolimbicocortical dopaminergic pathways via growth hormone secretagogue receptors (GHS-R1A) and nicotinic acetylcholine receptors (nAchR), respectively, resulting in the release of dopamine in the nucleus accumbens, the amygdala and the prefrontal cortex. In the present study an in vitro superfusion of rat amygdalar slices was performed in order to investigate the direct action of ghrelin and nicotine on the amygdalar dopamine release. Ghrelin increased significantly the dopamine release from the rat amygdala following electrical stimulation. This effect was inhibited by both the selective GHS-R1A antagonist GHRP-6 and the selective nAchR antagonist mecamylamine. Under the same conditions, nicotine also increased significantly the dopamine release from the rat amygdala. This effect was antagonized by mecamylamine, but not by GHRP-6. Co-administration of ghrelin and nicotine induced a similar increase of amygdalar dopamine release. This stimulatory effect was partially reversed by both GHRP-6 and mecamylamine. The present results demonstrate that both ghrelin and nicotine stimulates directly the dopamine release in the amygdala, an important dopaminergic target area of the mesolimbicocortical pathway.
- Published
- 2013
- Full Text
- View/download PDF
248. The interaction of Urocortin II and Urocortin III with amygdalar and hypothalamic cotricotropin-releasing factor (CRF)--reflections on the regulation of the hypothalamic-pituitary-adrenal (HPA) axis.
- Author
-
Bagosi Z, Csabafi K, Palotai M, Jászberényi M, Földesi I, Gardi J, Szabó G, and Telegdy G
- Subjects
- Amygdala drug effects, Animals, Corticosterone blood, Hypothalamo-Hypophyseal System metabolism, Hypothalamus drug effects, Male, Pituitary-Adrenal System metabolism, Rats, Rats, Wistar, Receptors, Corticotropin agonists, Urocortins pharmacology, Amygdala metabolism, Corticotropin-Releasing Hormone metabolism, Hypothalamus metabolism, Urocortins metabolism
- Abstract
Urocortin II (Ucn II) and Urocortin III (Ucn III) are selective agonists of the CRF receptor type 2 (CRFR2). The aim of the present experiments was to investigate the effects of Ucn II and Ucn III on the central CRF and peripheral glucocorticoids in rats. Increasing doses (0.5-1-2-5 μg/2 μl) of Ucn II or Ucn III were administered intracerebroventricularly, then CRF concentration was determined by immunoassays in two different brain regions, the amygdala and the hypothalamus, and in two different time paradigms, 5 and 30 min after the administration of peptides. In parallel with the second determination, plasma corticosterone concentration was measured by chemofluorescent assay. The amygdalar CRF amount was increased significantly by 0.5 and 5 μg of UCN II and 2 and 5 μg of UCN III in the 5 min experiments and by 5 μg of UCN II and 0.5 and 5 μg of UCN III in the 30 min experiments. The hypothalamic CRF content was not affected considerably in the 5 min paradigm, but it was influenced significantly in the 30 min paradigm, with 0.5 and 1 μg of UCN II and 0.5-2 μg of UCN III decreasing, and 2 and 5 μg of UCN II and 5 μg of UCN III increasing the hormone concentration, respectively. The plasma corticosterone concentration was decreased by 1 and 2 μg of UCN II and UCN III and increased by 0.5 and 5 μg of UCN III. The present results demonstrate that central administration of Ucn II and Ucn III modulate time-dependently and dose-dependently the amygdalar and the hypothalamic CRF concentration, and, directly or indirectly, the plasma corticosterone concentration. The present experiments suggest that the role of CRFR2 in the regulation of the HPA axis can be inhibitory or stimulatory, depending on the actual concentration of their agonists., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
249. Anxiolytic action of neuromedin-U and neurotransmitters involved in mice.
- Author
-
Telegdy G and Adamik A
- Subjects
- Adrenergic alpha-Antagonists pharmacology, Adrenergic beta-Antagonists pharmacology, Animals, Anti-Anxiety Agents, Atropine pharmacology, Dopamine Antagonists pharmacology, Haloperidol pharmacology, Male, Mice, Muscarinic Antagonists pharmacology, Neuropeptides pharmacology, Neurotransmitter Agents pharmacology, Nitric Oxide Synthase antagonists & inhibitors, Nitric Oxide Synthase metabolism, Nitroarginine pharmacology, Phenoxybenzamine pharmacology, Propranolol pharmacology, Anxiety metabolism, Neuropeptides physiology, Neurotransmitter Agents physiology
- Abstract
Peptide Neuromedin-U (NmU) is widely distributed in the central nervous system and the peripheral tissues. Its physiological effects include the regulation of blood pressure, heart rate, and body temperature, and the inhibition of gastric acid secretion. The action of NmU in rats is mediated by two G-protein-coupled receptors, NmU-1R and NmU-2R. NmU-2R is present mainly in the brain, and NmU-1R mainly in the periphery. Despite the great variety of the physiological action of NmU, little is known about its possible effects in different forms of behavior, such as anxiety. In the present work, NmU-23 (the rodent form of the peptide) was tested for its effect on anxiety in elevated plus maze test in mice. For detection of the possible involvement of neurotransmitters, the mice were pretreated with receptor blockers: haloperidol (a D2, dopamine receptor antagonist), propranolol (a β-adrenergic receptor antagonist), atropine (a nonselective muscarinic acetylcholine receptor antagonist), phenoxybenzamine (a nonselective α-adrenergic receptor antagonist) or nitro-l-arginine (a nitric oxide synthase inhibitor). The peptide and nitro-l-arginine were administered into the lateral brain ventricle, while the receptor blockers were applied intraperitoneally. An NmU-23 dose 0.5μg elicited anxiolytic action, whereas this action is faded away when the dose was increased. For further testing therefore 0.5μg i.c.v. was used. Propranolol and atropine fully blocked the NmU-induced anxiolytic action, while haloperidol, phenoxybenzamine and nitro-l-arginine were ineffective. The results suggest that β-adrenergic and cholinergic mechanisms are involved in the anxiolytic action of NmU., (© 2013.)
- Published
- 2013
- Full Text
- View/download PDF
250. Involvement of transmitters in the anxiolytic action of urocortin 3 in mice.
- Author
-
Telegdy G and Adamik A
- Subjects
- Analysis of Variance, Animals, Atropine therapeutic use, Bicuculline therapeutic use, Disease Models, Animal, Dose-Response Relationship, Drug, Haloperidol therapeutic use, Male, Maze Learning drug effects, Methysergide therapeutic use, Mice, Naloxone therapeutic use, Neurotransmitter Agents therapeutic use, Propranolol therapeutic use, Time Factors, Urocortins drug effects, Anxiety chemically induced, Neurotransmitter Agents metabolism, Urocortins toxicity
- Abstract
Urocortin 3 (Ucn 3) was tested for anxiolytic action in mice an elevated plus maze. For detection of the possible involvement of neurotransmitters, the mice were pretreated with receptor blockers: haloperidol, phenoxybenzamine, propranolol, atropine, methysergide, bicuculline or naloxone. The peptide was administered into the lateral brain ventricle; the receptor blockers were applied intra- peritoneally. Ucn 3 alone elicited dose-dependent bell-shaped anxiolytic action. The most effective dose was 0.5 μg. In the combined testing a 0.5 μg dose was used. Haloperidol, propranolol, atropine, methysergide, and naloxone, blocked the Ucn 3-induced anxiolytic action, while phenoxybenzamine and bicuculline were ineffective. The results suggest that dopaminergic, beta-adrenergic, cholinergic, serotonergic and opiate transmissions are involved in the anxiolytic action of Ucn 3., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.